Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Many congratulations to Dr Mark Hill, who has become a Fellow of the Society for Radiological Protection (FSRP).

Dr Mark Hill was awarded the honour of Fellow of the Society for Radiological Protection (FSRP) in recognition of his significant impact within the field of radiation protection.

Mark has over 30 years of experience in the field of radiation biology and physics. The main focus of his work relates to understanding the mechanisms behind how the spatial and temporal pattern of energy deposition by ionising radiation drives the subsequent biological response and ultimately the associated human health implications.

Alongside his research, Mark has been involved with a number of national and international committees, is Course Director of our MSc in Radiation Biology, lectures on the Annual Radiological Protection Summer School at University of Cambridge, and is a specialist radiobiology examiner on the First FRCR examination board for the Royal College of Radiologists. This year is also due to become a Member of the Committee on Medical Aspects of Radiation in the Environment (COMARE), which provides independent advice to all UK government departments and agencies.

Speaking of the award, Mark said “It is an honour to receive recognition from my peers for all the work I have done over the years”.

Similar stories

Scientists find genetic ‘marker’ linked to serious side-effects from skin cancer treatment

New research from the Fairfax Group has identified a genetic marker that could be used to predict a patient’s risk of developing serious side-effects when undergoing immunotherapy treatment for metastatic melanoma.

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the city’s two National Institute for Health and Care Research (NIHR) Biomedical Research Centres (BRC).

The Department represented at the European Radiation Research Society annual conference

Researchers from the Department of Oncology attend the prestigious European Radiation Research Society (ERRS) in annual conference in Catania, Italy to present their research in Radiation Oncology.

Funding to research metformin’s ability to delay or prevent cancers driven by the mutated TP53 gene

A research project embedded within the Metformin in Li Fraumeni (MILI) trial will investigate metformin’s mechanism of action when taken as a preventative for mTP53-driven cancers.

Cancer patients remain at higher risk of severe COVID-19 disease despite third dose booster vaccine

A large population-level assessment reveals third dose COVID-19 vaccination is effective for most patients with cancer, but effectiveness is lower than in the general population, particularly in patients who have undergone recent chemotherapy and those with lymphoma.